Pelthos Therapeutics (NYSE: PTHS) posts Q3 2025 earnings release

Rhea-AI Filing Summary

Pelthos Therapeutics Inc. filed a current report to let investors know it has released a press release with its financial results for the three and nine months ended September 30, 2025, and an update on its operations. The press release is included as Exhibit 99.1.

The company states that this earnings information and the exhibit are being "furnished" rather than "filed," which affects how they are treated under securities laws. The same information is also referenced for Regulation FD disclosure, signaling that Pelthos is using the press release and this report to provide broad, simultaneous access to its latest quarterly and year‑to‑date results.

false 0001919246 0001919246 2025-11-13 2025-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2025

Pelthos Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Nevada		001-41964		86-3335449
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

4020 Stirrup Creek Drive, Suite 110 Durham, NC		27703
(Address of registrant’s principal executive office)		(Zip code)

Registrant’s telephone number, including area code: (919) 908-2400

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		PTHS		The NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 13, 2025, Pelthos Therapeutics Inc. (the “Company”) issued a press release summarizing its financial results for the three and nine months ended September 30, 2025, as well as providing an update on the Company’s operations. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference.

The information in this Item 2.02 and Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 7.01. Regulation FD Disclosure.

The information disclosed in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is incorporated into this Item 7.01 by reference.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits:

Exhibit No.		Description
99.1		Press Release, dated November 13, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 13, 2025	Pelthos Therapeutics Inc.
	By:	/s/ Francis Knuettel II
		Name:	Francis Knuettel II
		Title:	Chief Financial Officer

FAQ

What did Pelthos Therapeutics (PTHS) disclose in this 8-K filing?

Pelthos Therapeutics Inc. disclosed that it issued a press release summarizing its financial results for the three and nine months ended September 30, 2025, and provided an update on its operations, furnished as Exhibit 99.1.

Which financial period does Pelthos Therapeutics (PTHS) cover in this update?

The update covers Pelthos Therapeutics Inc.'s financial results for the three and nine months ended September 30, 2025.

What is Exhibit 99.1 in the Pelthos Therapeutics (PTHS) 8-K?

Exhibit 99.1 is a press release dated November 13, 2025, in which Pelthos Therapeutics Inc. summarizes its financial results for the three and nine months ended September 30, 2025, and provides an operations update.

Is the Pelthos Therapeutics (PTHS) earnings press release considered "filed" with the SEC?

No. The company states that the information in Item 2.02 and Exhibit 99.1 is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.

Which items of Form 8-K does Pelthos Therapeutics (PTHS) use in this report?

Pelthos Therapeutics Inc. uses Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits).

Who signed the Pelthos Therapeutics (PTHS) 8-K report?

The report was signed on behalf of Pelthos Therapeutics Inc. by Francis Knuettel II, the company’s Chief Financial Officer.